← Back to all reports

Niemann-Pick Disease

Niemann-Pick Disease (NPD) encompasses a group of rare, genetic lysosomal storage disorders divided primarily into types A, B (also called acid sphingomyelinase deficiency, ASMD), and type C …

Published

Niemann-Pick Disease

Overview

Niemann-Pick Disease (NPD) encompasses a group of rare, genetic lysosomal storage disorders divided primarily into types A, B (also called acid sphingomyelinase deficiency, ASMD), and type C. These diseases are progressive and often fatal, particularly in their severe forms. NPD disrupts the body’s ability to process certain lipids, leading to their accumulation and damage in organs such as the brain, liver, lungs, and spleen.

Finding a cure for NPD has long been hampered by genetic and phenotypic diversity, slow progress in drug development for rare diseases, and technical obstacles in delivering therapies beyond symptom management. Today, however, there are several major breakthroughs, approved therapies, and new lines of research that give hope for real disease modification—and even cure.

Recent Major Research Breakthroughs and Therapies (2023–2025)

Enzyme Replacement and Substrate Reduction Therapies

1. Olipudase α (Xenpozyme) for ASMD (NPD A/B) A milestone in NPD treatment is the approval and clinical deployment of olipudase α, an enzyme replacement therapy (ERT) for acid sphingomyelinase deficiency (ASMD/NPD A/B). It replaces the deficient enzyme, clearing accumulated sphingomyelin and improving organ function, particularly in non-neurological manifestations See: Tirelli et al., 2024.

2. Miglustat has long served as a substrate reduction therapy (SRT) for neurological symptoms in NPD type C, slowing but not halting disease Tirelli et al., 2024.

3. Levacetylleucine (Aqneursa): FDA Approval 2024
A newly approved oral agent for neurological symptoms in Niemann-Pick C, levacetylleucine, targets cellular metabolism and substrate clearance. It offers meaningful clinical benefit and a new management standard for U.S. patients FDA Announcement, 2024.

4. Arimoclomol (Miplyffa): Disease-Modifying Approval in NPC
The major global breakthrough of the past two years is the U.S. FDA’s approval (September 2024) of arimoclomol (brand name Miplyffa) for NPD type C patients aged ≥2 years.
Arimoclomol acts as a “heat shock protein amplifier,” boosting cellular machinery to fold and clear misfolded proteins and dysfunctional lysosomes, thereby stabilizing disease progression.
- Arimoclomol pivotal and long-term clinical trial results confirm efficacy over several years, with strong real-world proof. - FDA PMC Publication, 2024
- Labiotech News

5. Next-Generation SRT: Nizubaglustat
The RAINBOW Phase 2 trial of nizubaglustat (Azafaros)—a new oral substrate reduction drug—showed encouraging safety and efficacy trends in NPD C, with further pivotal trials expected Nizubaglustat Results, Azafaros 2024.

6. Cyclodextrin (Trappsol® Cyclo™): Ongoing Phase 3 Study
Cyclo Therapeutics’s Trappsol® Cyclo™ Phase 3 global trial explores intravenous hydroxypropyl betacyclodextrin, a compound facilitating cholesterol and lipid export from cells—potentially slowing or halting NPD C progression.
- TransportNPC Study/Results (NCT04860960)
- Interim data show 86–87% stabilization/improvement in participants at 24 and 48 weeks Cyclo Therapeutics PR, 2025.

Gene and Genetic Substrate Reduction Therapies

Gene Therapy Advances: Optimized AAV9-hNPC1 in Mice
In a recent preclinical study, systemic delivery of gene therapy using AAV9 vectors carrying a healthy copy of the NPC1 gene, when administered early and at higher doses, showed dramatic improvement in lifespan and neurological function in mouse models Mylvara et al., 2024 bioRxiv.
These findings define key parameters—such as timing and dose—for any future clinical translation of gene therapy in humans. Although no clinical trials are yet registered for gene therapy in NPD (as of mid-2025), imminent translation is likely if preclinical safety is confirmed.

Genome Editing and Nucleic Acid Therapies: Emerging Directions
Genetic substrate reduction therapies using siRNA and CRISPR/Cas9 gene editing are in early experimental/preclinical stages for lysosomal storage diseases, including NPD. While these have not yet reached clinical trial for NPD, they are considered very promising for the coming years Beraza-Millor et al., 2024.

Cell and Other Experimental Therapies

While stem cell and chaperone-based therapies remain mostly preclinical, major reviews report active efforts to optimize cell transplantation, molecular chaperones, HDAC inhibitors, and repurposed small molecules for NPD type C Li & Li, 2024.

Clinical Trials: The Most Recent and Impactful Studies

1. TransportNPC—Trappsol® Cyclo™ (Cyclo Therapeutics, NCT04860960)

  • Type: Phase 3, double-blind, randomized, placebo-controlled
  • Modality: Intravenous cyclodextrin for NPD C
  • Status: Ongoing, completion May 2024
  • Preliminary Results: 86–87% stabilization/improvement
    Trial Registry & Outcome | Cyclo PR

2. Arimoclomol/Miplyffa (Zevra Therapeutics, NCT02612129)

  • Type: Completed pivotal Phase 2/3 & long-term extensions, multicenter
  • Modality: Heat-shock protein amplifier (oral)
  • FDA approval: September 2024
  • Impact: First disease-modifying therapy for NPD C, new standard of care Trial details | FDA news

3. Nizubaglustat (RAINBOW Study, Azafaros)

  • Type: Phase 2, randomized, double-blind, placebo-controlled (NPD C and GM2)
  • Status: Completed Q1 2024; topline results July 2024
  • Results: Good tolerability, positive early efficacy Sponsor update

Notably, no phase 2+ gene therapy, ERT, or cell therapy clinical trials for NPD A/B or ASMD were found during this period; nearly all regulatory/funding activity focuses on NPD type C.

Methodologies, Key Players, and Funding

Methodologies & Approaches

  • Randomized, double-blind clinical trials (global, multinational)
  • Open-label extension studies for long-term efficacy and safety
  • Advanced preclinical models (transgenic mice, cell culture)
  • Biomarker-based monitoring and improved diagnostic criteria Mancini et al., 2024

Leading Institutions & Sponsors

  • Major academic centers: UCSF, NIH, University of Milan, among others
  • Industry players: Zevra Therapeutics, Cyclo Therapeutics, Azafaros BV
  • Funding: NIH/NINDS, EC-funded programs, disease-specific foundations (e.g., National Niemann-Pick Disease Foundation, NNPDF)

Key Trends

  • First-ever disease-modifying drug approvals for NPD C (arimoclomol, levacetylleucine), shifting management toward meaningful clinical stability.
  • Highly collaborative, multinational trial designs raise trial power and external validity.
  • Strong translational focus on gene therapy and novel SRTs for possible future “cure.”

Critical Analysis: Strengths, Limitations & Remaining Challenges

Strengths

  • Emergence of disease-modifying drugs for NPD C is a scientific and regulatory breakthrough offering hope for patients who previously had little therapeutic recourse.
  • Innovations in genetic and molecular research are enabling leapfrogging progress in gene therapy, SRT, and biomarker discovery.

Limitations

  • Most transformative advances (gene therapy, gene editing) remain preclinical as of 2025; mouse studies are promising, but translation to humans still faces challenges: immune system reaction, gene delivery, CNS penetration, accurate patient selection, and early diagnosis.
  • Nearly all drug and trial development focuses on NPD type C—leaving NPD types A and B still with extremely limited options, largely restricted to enzyme replacement and symptom management.
  • Regulatory approval processes for rare (“orphan”) diseases are slow; some drugs face funding/manufacturing constraints or fail to demonstrate strong effect in global cohorts.
  • Clinical trial recruitment is complicated by the ultra-rare nature of the diseases.

Challenges Remaining

  • Delivering gene therapy and genome editing safely and effectively, especially across the blood-brain barrier and in infants/small children.
  • Extending meaningful therapies (or gene editing) to non-C subtypes and to adult patients.
  • Funding, trial design, and regulatory navigation for ultra-rare, heterogeneous diseases.
  • Managing long-term safety, potential toxicity, and equitable global access to expensive therapies.
  • Need for improved or earlier diagnosis to enable timely intervention.

Looking Forward: The Future of NPD Cure Research

  • The next few years will likely see the launch of first-in-human gene therapy trials for NPD C, based on preclinical AAV breakthroughs.
  • Parallel work on genome editing, molecular chaperones, and combination therapies is ongoing and moving closer to clinical trials.
  • Precision diagnostics and improved biomarker panels will help tailor therapies and monitor efficacy.
  • Global collaborations between patient foundations, pharma, governments, and academia are accelerating research, regulatory, and funding efforts.

Even with major progress, a definitive “cure” remains on the horizon—for NPD type C first, with hope that insights and methods will spill over into the much rarer types A and B.

References & Further Reading

Last updated: May 30, 2025.

Don't see your disease? Request a report